The global landscape for AI-enabled medical devices is rapidly evolving, with the two largest markets, the United States and the European Union, charting distinct regulatory courses. This episode of MedTech Global Insights provides a crucial breakdown of the fundamental differences between the FDA's iterative, change-oriented framework and the EU's comprehensive dual-system of the MDR and the new AI Act. We delve into the practical implications these differences have on product development, data governance, and post-market updates. For MedTech innovators, understanding these diverging requirements is the key to designing a successful global market access strategy, preventing costly delays, and ensuring your breakthrough technology can reach patients worldwide. Consider this scenario. Your company has developed a groundbreaking AI diagnostic tool that continuously learns from new data to improve its accuracy. In the U.S., the FDA's Predetermined Change Control Plan (PCCP) could provide a clear and efficient pathway to deploy these updates. However, how do you manage the same adaptive algorithm in the EU, where the new AI Act imposes strict, additional requirements for data quality, transparency, and human oversight on top of the MDR. A misstep in navigating this dual-layered system could leave your "smart" device locked out of the entire European market. Key Takeaways: 1. What is an FDA Predetermined Change Control Plan (PCCP) and how can it accelerate your product's lifecycle? 2. How does the EU's new AI Act interact with the existing Medical Device Regulation (MDR) for software devices? 3. Why might your FDA submission strategy be entirely insufficient for securing a CE mark in Europe? 4. What are the critical differences in data quality and transparency requirements between the two regions? 5. How do regulators in the US and EU view "locked" versus "adaptive" or continuously learning AI algorithms differently? 6. What are the most significant compliance risks for MedTech companies targeting both US and EU markets? 7. How is the principle of "human oversight" for AI systems defined and enforced in each regulatory framework? 8. What new documentation is required under the EU AI Act that is not part of a standard FDA submission? For more information, contact us at [email protected] or visit https://pureglobal.com/.